Results 111 to 120 of about 1,269,047 (315)

Immunological & microbiological reference reagents

Prepared by the Biological Reagents Section and distributed for reference use by the Scientific Resources Branch, Laboratory Division, Center for Disease Control.Bibliography : p.

core  

Allylic organobismetallic reagents - part 1

, 1989
Allyl-allenyl zinc reagents undergo a rearrangement leading to allylic bis metallic species. A high regioselectivity is observed when these reagents are treated with a variety of electrophiles.
Quirion, J.Ch., Alexakis, Alexandre, A. Alexakis, Y. Masuda, J.F. Normant, Normant, Jean F., Masuda, Y., J.Ch. Quirion   +7 more
core   +1 more source

Copper Sulfate (CuSO₄): An Efficient Reagent in Organic Synthesis

SynOpen, 2023
Housemberg D. S. Ferrreira, Euzébio G. Barbosa, Alessandro K. Jordão   +2 more
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Stoichiometric and irreversible cysteine-selective protein modification using carbonylacrylic reagents

, 2016
Maleimides remain the reagents of choice for the preparation of therapeutic and imaging protein conjugates despite the known instability of the resulting products that undergo thiol-exchange reactions $\textit{in vivo}$.
Bernardim, Barbara, Bernardes, GJL, Corzana, F., Albuquerque, IS, Perkins, E., Oliveira, BL, Martínez-Saéz, N., Albuquerque, I.S., Bernardim, B, Martínez-Saéz, N. [0000-0002-0799-5106], Perkins, E, Matos, M.J. [0000-0002-3470-8299], Jiménez-Osés, G., Matos, M.J., Bernardes, Gonçalo J. L., Jiménez-Osés, G. [0000-0003-0105-4337], Bernardes, G.J.L. [0000-0001-6594-8917], Corzana, Francisco, Corzana, F. [0000-0001-5597-8127], Cal, PMSD, Burtoloso, ACB, ,, Bernardim, B., Corzana, F, Cal, P.M.S.D., Bernardes, G.J.L., Oliveira, B.L. [0000-0002-7687-4746], Matos, MJ, Albuquerque, I.S. [0000-0002-1108-0961], Oliveira, B.L., Burtoloso, A.C.B., Martínez-Sáez, N, Jiménez-Osés, Gonzalo, Jiménez-Osés, G   +33 more
core   +1 more source

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

Molecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski, Liudmyla Dolinchuk, Michał Jerzak, Albert Gandurski, Tomasz Grochowski, Weronika Wojtyś, Maciej Zadrożny, Wojciech Kaźmierczak, Małgorzata Lenarcik, Marta Matejak‐Górska, Radosław Samsel, Tomasz Olesiński, Dawid Walerych   +12 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

reagent

, 2014
Citation: 'reagent' in the IUPAC Compendium of Chemical Terminology, 3rd ed.; International Union of Pure and Applied Chemistry; 2006. Online version 3.0.1, 2019. 10.1351/goldbook.R05190 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms. Requests for commercial usage
openaire   +2 more sources

An approach to identifying quality research antibodies

BioTechniques, 2022
Katherine Groff, David Allen, Michael Fiebig, Pierre Cosson, Warren Casey, Amy J Clippinger   +5 more
doaj   +1 more source